{"id":"dual-antithrombotc-therapy-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal hemorrhage"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Bruising"}]},"_chembl":{"chemblId":"CHEMBL5984914","moleculeType":null,"molecularWeight":"296.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination therapy typically pairs an antiplatelet agent (such as aspirin or a P2Y12 inhibitor) with another antiplatelet drug to provide synergistic inhibition of platelet function through distinct mechanisms. The dual approach reduces the risk of stent thrombosis, myocardial infarction, and stroke by preventing platelet-mediated clot formation more effectively than monotherapy.","oneSentence":"Dual antiplatelet therapy combines two agents that work through different pathways to inhibit platelet aggregation and reduce thrombotic events.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:35:41.306Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Percutaneous coronary intervention with stent placement"},{"name":"Secondary prevention of myocardial infarction and stroke"}]},"trialDetails":[{"nctId":"NCT03234114","phase":"PHASE4","title":"Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-02-03","conditions":"Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)","enrollment":3746}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":78,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DAT-1"],"phase":"marketed","status":"active","brandName":"Dual antithrombotc therapy-1","genericName":"Dual antithrombotc therapy-1","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dual antiplatelet therapy combines two agents that work through different pathways to inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Secondary prevention of myocardial infarction and stroke.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}